The introduction of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable buzz within the medical community. This innovative dual GIP and GLP-1 target medication appears to offer significant improvements in body loss compared to current therapies. Initial research data have shown substantial reductions in weight , potentially represent